MoonLake Immunotherapeutics宣布，其与美国食品药品监督管理局（FDA）就关键候选产品进行的最终生物制品许可申请（BLA）前会议取得了积极成果。公司管理层与监管机构就提交BLA所需的数据包和路径达成了一致，这标志着其药物开发进程中的一个重要监管里程碑。
与此同时，公司公布了2026年第一季度的财务业绩。财报显示，本季度研发投入显著，主要用于推进其核心管线项目。尽管研发费用增加导致净亏损有所扩大，但公司现金及现金等价物状况依然稳健，足以支持其未来数年的运营和关键临床开发计划。管理层对取得的进展表示满意，并期待按计划向FDA正式提交BLA申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.